The Stock Exchange of Hong Kong Limited has taken disciplinary action against two former directors of China Health Technology Group Holding Company Limited, previously known as China Bozza Development Holdings Limited (Stock Code: 1069). The Exchange issued a Director Unsuitability Statement and censured Mr. Wang Yue, a former executive director, and Ms. Tian Guangmei, a former independent non-executive director, deeming them unsuitable for any director or senior management roles within the company or its subsidiaries. This action follows their involvement in the approval and extension of loans totaling HK$138.3 million between 2015 and 2019, alongside their failure to cooperate with the Exchange's investigation. The disciplinary measures are solely applicable to the two individuals and not to the company or its other directors. The announcement was made on May 28, 2025.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。